Invasive Bladder Cancer Clinical Trial
Official title:
Pilot Testing for Post-Cystectomy mHealth Tool to Improve Perioperative Care
NCT number | NCT03862105 |
Other study ID # | LCCC1856 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | March 25, 2019 |
Est. completion date | April 27, 2020 |
Verified date | June 2020 |
Source | UNC Lineberger Comprehensive Cancer Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a pilot study that involves human subjects undergoing cystectomy surgery for bladder cancer, testing the utilization of a mobile health app that promotes postoperative patient engagement, along with provider monitoring and care. The aim of this pilot study is to assess feasibility and acceptability of an Internet-based mobile health tool following cystectomy discharge. Objectives will be met by assessing weekly adherence, determining acceptability of mobile health questions post-surgery by patients and providers, and by obtaining participant feedback regarding the tool. Complications, re-admissions, and resource utilization will also be monitored throughout the study. The hypothesis is that an mobile health intervention that tracks PROs, provides educational content, and allows real-time feedback via internet-enabled devices has the potential to improve the quality of care delivery and overall patient experience following surgery by decreasing resource utilization and improving symptom control and communication.
Status | Completed |
Enrollment | 33 |
Est. completion date | April 27, 2020 |
Est. primary completion date | April 27, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 100 Years |
Eligibility |
Minimum Age: 18 Years Maximum Age: 99 Years Sex: All Gender Based: No Criteria: Inclusion Criteria: - Male or female patients with invasive bladder cancer scheduled for radical cystectomy at UNC within the next 30 days - English-speaking - Ability to access the Internet (either themselves or with assistance from their caregiver) - Ability to read - Ability to provide informed consent. Exclusion Criteria: - Inability to read - Inability to provide informed consent - Severe psychiatric illness - Cystectomy surgery without cancer diagnosis - Non-English speaking |
Country | Name | City | State |
---|---|---|---|
United States | Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill | Chapel Hill | North Carolina |
Lead Sponsor | Collaborator |
---|---|
UNC Lineberger Comprehensive Cancer Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Feasibility of the tool (Twistle): percentage of patients using the tool at least once weekly | percentage of patients using the tool at least once weekly | 90 days postoperative | |
Secondary | Acceptability of tool (Twistle): Percentage of patients being satisfied or very satisfied with the mobile health tool | Percentage of patients being satisfied or very satisfied with the mobile health tool, determined through an online post-intervention survey, addressing ease of use, convenience, privacy and confidentiality, and willingness to use the tool. | 90 days postoperative |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04537221 -
Nordic Cystectomy Study III - Transfusion
|
||
Completed |
NCT02924480 -
Intravenous Lidocaine for Cystectomy Procedures
|
N/A | |
Recruiting |
NCT05783271 -
Multiparametric Magnetic Resonance Imaging Performance in Detection of Occult Muscle Invasion in Urinary Bladder Cancer
|
||
Active, not recruiting |
NCT03702179 -
Durvalumab Plus Tremelimumab With Concurrent Radiotherapy for Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation Approach
|
Phase 2 | |
Recruiting |
NCT02560636 -
Pembrolizumab in Muscle Invasive/Metastatic Bladder Cancer
|
Phase 1 | |
Active, not recruiting |
NCT02030574 -
Neoadjuvant Gemcitabine and Fractionated, Weekly Cisplatin For Muscle Invasive Bladder Cancer and Patients Not Candidates For High Dose Cisplatin
|
Phase 2 | |
Recruiting |
NCT03844256 -
A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04134000 -
Atezolizumab and BCG in High Risk BCG naïve Non-muscle Invasive Bladder Cancer (NMIBC) Patients (BladderGATE)
|
Phase 1 | |
Terminated |
NCT03498196 -
A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT04523025 -
Nordic Cystectomy Study I - Neutrophil-lymphocyte Ratio (NLR)
|
||
Recruiting |
NCT04523038 -
Nordic Cystectomy Study II - Albumin
|
||
Withdrawn |
NCT01922232 -
MRI and Bladder Cancer Chemotherapy
|
N/A | |
Completed |
NCT03514888 -
HIPEC After Radical Cystectomy for High Risk Bladder Cancer
|
N/A |